biostudies-literatureLiao WScience and Technology Department of Sichuan Province Funding Project17588359241274625https://www.ebi.ac.uk/biostudies/studies/S-EPMC11412210biostudies-literatureUnknown16<h4>Background</h4>The HIMALAYA trial found that durvalumab plus tremelimumab significantly prolonged progression-free survival and overall survival in patients with unresectable hepatocellular carcinoma (HCC) compared with sorafenib.<h4>Objective</h4>This study aimed to investigate the cost-effectiveness of durvalumab plus tremelimumab compared with sorafenib in the first-line HCC setting.<h4>Design</h4>A Markov model-based cost-effectiveness analysis.<h4>Methods</h4>We created a Markov model to compare healthcare costs and clinical outcomes of HCC patients treated with durvalumab plus tremelimumab in the first-line setting compared with sorafenib. We estimated transition probabilities from randomized trials. Lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and increTherapeutic advances in medical oncologyCost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma.PMC114122102016FZ0108, 18ZDYF1981Yang YFeng MLi JHutton DWu QLiao WLei WBai LLi QXu HfalseCost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma.<h4>Background</h4>The HIMALAYA trial found that durvalumab plus tremelimumab significantly prolonged progression-free survival and overall survival in patients with unresectable hepatocellular carcinoma (HCC) compared with sorafenib.<h4>Objective</h4>This study aimed to investigate the cost-effectiveness of durvalumab plus tremelimumab compared with sorafenib in the first-line HCC setting.<h4>Design</h4>A Markov model-based cost-effectiveness analysis.<h4>Methods</h4>We created a Markov model to compare healthcare costs and clinical outcomes of HCC patients treated with durvalumab plus tremelimumab in the first-line setting compared with sorafenib. We estimated transition probabilities from randomized trials. Lifetime direct healthcare costs, quality-adjusted life-years (QALYs), and incre2024-01-01T00:00:00Z20242026-06-03T23:45:36.218Z2025-04-07T07:33:30.011ZS-EPMC114122103930113810.1177/17588359241274625